Mediolanum International Funds Ltd Purchases 20,337 Shares of DexCom, Inc. (NASDAQ:DXCM)

Mediolanum International Funds Ltd lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 18.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 127,725 shares of the medical device company’s stock after purchasing an additional 20,337 shares during the quarter. Mediolanum International Funds Ltd’s holdings in DexCom were worth $8,580,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC lifted its position in DexCom by 11.4% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 25,322 shares of the medical device company’s stock valued at $3,512,000 after acquiring an additional 2,591 shares in the last quarter. Hodges Capital Management Inc. purchased a new position in shares of DexCom during the first quarter valued at approximately $347,000. Toth Financial Advisory Corp boosted its position in shares of DexCom by 870.9% during the first quarter. Toth Financial Advisory Corp now owns 6,583 shares of the medical device company’s stock valued at $913,000 after buying an additional 5,905 shares during the last quarter. Trilogy Capital Inc. bought a new stake in DexCom during the first quarter worth $470,000. Finally, Congress Wealth Management LLC DE raised its position in DexCom by 0.6% in the 1st quarter. Congress Wealth Management LLC DE now owns 168,657 shares of the medical device company’s stock valued at $23,393,000 after buying an additional 952 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the sale, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,824 shares of company stock valued at $126,390 in the last ninety days. Company insiders own 0.30% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $73.44 on Friday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The company has a market cap of $29.21 billion, a PE ratio of 47.38, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The stock has a 50-day moving average price of $70.11 and a 200-day moving average price of $98.24.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 24th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.02. The business had revenue of $994.20 million during the quarter, compared to analyst estimates of $991.55 million. DexCom had a net margin of 16.95% and a return on equity of 31.41%. As a group, equities analysts forecast that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on DXCM shares. Stifel Nicolaus upped their target price on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Robert W. Baird upped their price objective on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Morgan Stanley reduced their price objective on DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a report on Friday, July 26th. Oppenheimer lowered their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday. Finally, StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Friday. Six equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.